Pakistan’s path forward in DR-TB management: insights from global implementation of BPaL/BPaLM regimen
Open Access
- 10 July 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 4713-4717
Abstract
Drug-resistant tuberculosis (DR-TB) is a serious public health threat, and Pakistan is one of the most impacted nations. The long treatment duration of traditional regimens puts a great burden on healthcare systems, especially in resource-constrained environments. Accordingly, the World Health Organization launched the Bedaquiline, Pretomanid, and Linezolid (BPaL)/Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin (BPaLM) regimen – a 6-month, all-oral therapy consisting of BPaLM. With stated success rates as high as 90%, these regimens present an exciting alternative to traditional treatments. Yet, their integration into current treatment programs is hindered by policy lags, poor diagnostic infrastructure, and difficulty in maintaining patient compliance. This brief communication explores the promise of BPaL/BPaLM to enhance DR-TB cure rates while pinpointing major hurdles to its use in Pakistan. Enhancing diagnostic capacity, upgrading healthcare infrastructure, and accelerating policy adjustment are crucial steps toward maximizing DR-TB management in high-burden countries.Keywords
This publication has 12 references indexed in Scilit:
- Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysisPLOS ONE, 2024
- Savings from the introduction of BPaL and BPaLM regimens at the country levelIJTLD OPEN, 2024
- Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the PhilippinesIJTLD OPEN, 2024
- Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysisPLOS Medicine, 2024
- The use of BPaL containing regimen in the MDR/PreXDR TB treatments in ThailandJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2023
- Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South AfricaSouth African Medical Journal, 2023
- Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant TuberculosisNew England Journal of Medicine, 2022
- Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesBMJ Open, 2021
- Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patientsBMC Public Health, 2021
- WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment2020